Akèy › Kansè nan tete › Michigan › Detroit
Etid klinik pou Kansè nan tete nan Detroit, MI
33 etid pou Kansè nan tete ap chèche patisipan nan sit nan ak bò kote Detroit (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
The Vanguard Study: Testing a New Way to Screen for Cancer
Ap rekriteVolontè an sante akeyi
- Henry Ford Hospital, Detroit
- Henry Ford Medical Center - Detroit Northwest, Detroit
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Ap rekriteFaz 2
- Henry Ford Hospital, Detroit
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Ap rekriteFaz 3
- Henry Ford Health ( Site 0002), Detroit
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Ap rekriteFaz 3
- Research Site, Detroit
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Ap rekrite
- Karmanos Cancer Center - Wayne State University, Detroit
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Ap rekriteFaz 1
- Barbara Ann Karmanos Cancer Institute, Detroit
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Ap rekriteFaz 1
- Barbara Ann Karmanos Cancer Institute, Detroit
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Ap rekriteFaz 3
- Henry Ford Hospital, Detroit
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Ap rekriteFaz 1/2
- Karmanos Cancer Institute, Detroit
- Brigitte Harris Cancer Pavilion BHCP, Detroit
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Ap rekriteFaz 3
- Karmanos Cancer Center, Detroit
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Ap rekriteFaz 1
- Karmanos Cancer Institiute, Detroit
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Ap rekriteFaz 1
- Henry Ford Cancer Institute, Detroit
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Ap rekriteFaz 1/2
- Henry Ford Hospital, Detroit
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Ap rekriteFaz 1/2
- Wayne State University - Barbara Ann Karmanos Cancer Institute, Detroit
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Ap rekriteFaz 3
- Henry Ford Health System, Detroit
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Ap rekriteFaz 3
- Wayne State University/Karmanos Cancer Institute, Detroit
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer
Ap rekrite
- Karmanos Cancer Institute, Detroit
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Ap rekriteFaz 3
- Wayne State University/Karmanos Cancer Institute, Detroit
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Ap rekriteFaz 2/3
- Henry Ford Cancer- Detroit (Brigitte Harris Cancer Pavilion), Detroit
E-Mindfulness Approaches for Living After Breast Cancer
Ap rekriteFaz 3
- Henry Ford Hospital, Detroit
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Ap rekriteFaz 1/2
- Karmanos Cancer Institute, Detroit
Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
Ap rekriteVolontè an sante akeyi
- Henry Ford Health, Detroit
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Ap rekriteFaz 1/2
- Henry Ford Health Hospital, Detroit
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Ap rekriteFaz 1/2
- Henry Ford Hospital, Detroit
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Ap rekriteFaz 3
- Henry Ford Health System, Detroit
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Ap rekriteFaz 3
- Wayne State University/Karmanos Cancer Institute, Detroit
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
A Study of the TheraBionic P1 Device in Breast Cancer
Ap rekrite
- Karmanos Cancer Institute, Detroit
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Henry Ford Health System, Detroit
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Ap rekriteFaz 1/2
- Karmanos Cancer Institute, Detroit
F-Tryptophan PET/CT in Human Cancers
Ap rekriteFaz 1
- Karmanos Cancer Institute, Detroit
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Ap rekriteFaz 3
- Wayne State University/Karmanos Cancer Institute, Detroit
- Henry Ford Hospital, Detroit
A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.
Ap rekrite
- Karmanos Cancer Institute, Detroit
Etid Kansè nan tete nan lòt vil
- New York City, NY136 etid
- Houston, TX126 etid
- Boston, MA112 etid
- Nashville, TN81 etid
- Los Angeles, CA73 etid
- Edison, NJ68 etid
- St. Louis, MO64 etid
- Queens, NY64 etid
- Durham, NC64 etid
- Chicago, IL59 etid
- Philadelphia, PA56 etid
- Dallas, TX55 etid
Lòt etid nan Detroit
- Kansè Poumon ki pa ti selil44 etid
- Kansè (tout kalite)29 etid
- Kansè kolorektal26 etid
- Kansè ovè26 etid
- Kansè Metastatik24 etid
- Kansè pwostat22 etid
- Kansè Endomèt21 etid
- Kansè poumon20 etid
- Myelom Miltip19 etid
- Kansè lestomak16 etid
- Karsinòm selil skuamèz tèt ak kou15 etid
- Leksemi mieloïd egi14 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.